1
|
Bellomo R, Kellum JA and Ronco C: Acute
kidney injury. Lancet. 380:756–766. 2012.PubMed/NCBI View Article : Google Scholar
|
2
|
Vijayan A, Faubel S, Askenazi DJ, Cerda J,
Fissell WH, Heung M, Humphreys BD, Koyner JL, Liu KD, Mour G, et
al: American Society of Nephrology Acute Kidney Injury Advisory
Group: Clinical use of the urine biomarker [TIMP-2]x[IGFBP7] for
acute kidney injury risk assessment. Am J Kidney Dis. 68:19–28.
2016.PubMed/NCBI View Article : Google Scholar
|
3
|
Szeto CC, Li PK, Johnson DW, Bernardini J,
Dong J, Figueiredo AE, Ito Y, Kazancioglu R, Moraes T, Van Esch S,
et al: ISPD catheter-related infection recommendations: 2017
update. Perit Dial Int. 37:141–154. 2017.PubMed/NCBI View Article : Google Scholar
|
4
|
Doi K and Rabb H: Impact of acute kidney
injury on distant organ function: Recent findings and potential
therapeutic targets. Kidney Int. 89:555–564. 2016.PubMed/NCBI View Article : Google Scholar
|
5
|
Mennerich D, Vogel A, Klaman I, Dahl E,
Lichtner RB, Rosenthal A, Pohlenz HD, Thierauch KH and Sommer A:
Shift of syndecan-1 expression from epithelial to stromal cells
during progression of solid tumours. Eur J Cancer. 40:1373–1382.
2004.PubMed/NCBI View Article : Google Scholar
|
6
|
Lu Z, Song N, Shen B, Xu X, Fang Y, Shi Y,
Ning Y, Hu J, Dai Y, Ding X, et al: Syndecan-1 shedding inhibition
to protect against ischemic acute kidney injury through HGF target
signaling pathway. Transplantation. 102:e331–e344. 2018.PubMed/NCBI View Article : Google Scholar
|
7
|
Junior GS, Sobral D, Cavalcante MG,
Meneses G, Martins A and Daher E: Novel biomarkers of kidney injury
and endothelial dysfunction among HIV patients. Int J Infect Dis.
73(252)2018.
|
8
|
Gill SE, Nadler ST, Li Q, Frevert CW, Park
PW, Chen P and Parks WC: Shedding of syndecan-1/CXCL1 complexes by
matrix metalloproteinase 7 functions as an epithelial checkpoint of
neutrophil activation. Am J Respir Cell Mol Biol. 55:243–251.
2016.PubMed/NCBI View Article : Google Scholar
|
9
|
Wang X, Zuo D, Chen Y, Li W, Liu R, He Y,
Ren L, Zhou L, Deng T, Wang X, et al: Shed Syndecan-1 is involved
in chemotherapy resistance via the EGFR pathway in colorectal
cancer. Br J Cancer. 111:1965–1976. 2014.PubMed/NCBI View Article : Google Scholar
|
10
|
Li F, Majd H, Weir MD, Arola DD and Xu HH:
Inhibition of matrix metalloproteinase activity in human dentin via
novel antibacterial monomer. Dent Mater. 31:284–292.
2015.PubMed/NCBI View Article : Google Scholar
|
11
|
Makris K and Spanou L: Acute kidney
injury: Definition, pathophysiology and clinical phenotypes. Clin
Biochem Rev. 37:85–98. 2016.PubMed/NCBI
|
12
|
Brauer R, Ge L, Schlesinger SY, Birkland
TP, Huang Y, Parimon T, Lee V, McKinney BL, McGuire JK, Parks WC,
et al: Syndecan-1 attenuates lung injury during influenza infection
by potentiating c-met signaling to suppress epithelial apoptosis.
Am J Respir Crit Care Med. 194:333–344. 2016.PubMed/NCBI View Article : Google Scholar
|
13
|
Gandley RE, Althouse A, Jeyabalan A,
Bregand-White JM, McGonigal S, Myerski AC, Gallaher M, Powers RW
and Hubel CA: Low soluble syndecan-1 precedes preeclampsia. PLoS
One. 11(e0157608)2016.PubMed/NCBI View Article : Google Scholar
|
14
|
Götte M, Kersting C, Ruggiero M, Tio J,
Tulusan AH, Kiesel L and Wülfing P: Predictive value of syndecan-1
expression for the response to neoadjuvant chemotherapy of primary
breast cancer. Anticancer Res. 26B:621–627. 2006.PubMed/NCBI
|
15
|
Jing Z, Wei-Jie Y, Yi-Feng ZG and Jing H:
Downregulation of Syndecan-1 induce glomerular endothelial cell
dysfunction through modulating internalization of VEGFR-2. Cell
Signal. 28:826–837. 2016.PubMed/NCBI View Article : Google Scholar
|
16
|
Schmidt M, Mansfield KE, Bhaskaran K,
Nitsch D, Sørensen HT, Smeeth L and Tomlinson LA: Serum creatinine
elevation after renin-angiotensin system blockade and long term
cardiorenal risks: cohort study. BMJ356. (j791)2017.PubMed/NCBI View
Article : Google Scholar
|
17
|
Zhang Z, Zhao J, Dong W, Remer E, Li J,
Demirjian S, Zabell J and Campbell SC: Acute kidney injury after
partial nephrectomy: Role of parenchymal mass reduction and
ischemia and impact on subsequent functional recovery. Eur Urol.
69:745–752. 2016.PubMed/NCBI View Article : Google Scholar
|
18
|
Tsuji T, Ohishi K, Takeda A, Goto D, Sato
T, Ohashi N, Fujigaki Y, Kato A and Yasuda H: The impact of serum
uric acid reduction on renal function and blood pressure in chronic
kidney disease patients with hyperuricemia. Clin Exp Nephrol.
22:1300–1308. 2018.PubMed/NCBI View Article : Google Scholar
|
19
|
Wong J, Sridharan S, Berdeprado J, Vilar
E, Viljoen A, Wellsted D and Farrington K: Predicting residual
kidney function in hemodialysis patients using serum β-trace
protein and β2-microglobulin. Kidney Int. 89:1090–1098.
2016.PubMed/NCBI View Article : Google Scholar
|
20
|
de Melo Bezerra Cavalcante CT, Castelo
Branco KM, Pinto Júnior VC, Meneses GC, de Oliveira Neves FM, de
Souza NM, Penaforte KL, Martins AM and Libório AB: Syndecan-1
improves severe acute kidney injury prediction after pediatric
cardiac surgery. J Thorac Cardiovasc Surg. 152:178–186.e2.
2016.PubMed/NCBI View Article : Google Scholar
|
21
|
Mosaad NA, Lotfy HM, Farag YM, Mahfouz RH
and Shahin RM: Study of serum syndecan-1 levels in a group of
Egyptian juvenile systemic lupus erythematosus patients. Immunol
Lett. 181:16–19. 2017.PubMed/NCBI View Article : Google Scholar
|
22
|
Kato M, Wang H, Kainulainen V, Fitzgerald
ML, Ledbetter S, Ornitz DM and Bernfield M: Physiological
degradation converts the soluble syndecan-1 ectodomain from an
inhibitor to a potent activator of FGF-2. Nat Med. 4:691–697.
1998.PubMed/NCBI View Article : Google Scholar
|
23
|
Xiong C, Zang X, Zhou X, Liu L, Masucci
MV, Tang J, Li X, Liu N, Bayliss G, Zhao TC, et al: Pharmacological
inhibition of Src kinase protects against acute kidney injury in a
murine model of renal ischemia/reperfusion. Oncotarget.
8:31238–31253. 2017.PubMed/NCBI View Article : Google Scholar
|
24
|
Zeng Y, Yao X, Chen L, Yan Z, Liu J, Zhang
Y, Feng T, Wu J and Liu X: Sphingosine-1-phosphate induced
epithelial-mesenchymal transition of hepatocellular carcinoma via
an MMP-7/ syndecan-1/TGF-β autocrine loop. Oncotarget.
7:63324–63337. 2016.PubMed/NCBI View Article : Google Scholar
|
25
|
Dolmatov IY, Shulga AP, Ginanova TT,
Eliseikina MG and Lamash NE: Metalloproteinase inhibitor GM6001
delays regeneration in holothurians. Tissue Cell. 59:1–9.
2019.PubMed/NCBI View Article : Google Scholar
|
26
|
Liu X and Han Q: Efficacy of GM6001 as an
adjuvant to ceftriaxone in a neonatal rat model of Streptococcus
pneumoniae meningitis. Acta Neurobiol Exp (Wars). 74:489–496.
2014.PubMed/NCBI
|